# Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study

> **NCT06435702** · — · NOT_YET_RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 108 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Darolutamide in addition to androgen deprivation therapy
- **DRUG:** androgen deprivation therapy only

## Key facts

- **NCT ID:** NCT06435702
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2029-12-31
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2024-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06435702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06435702, "Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06435702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*